Pfizer, Inc. : Back on a long term support level
Entry price | Target | Stop-loss | Potential |
---|
US$32.83 |
US$36.9 |
US$31.9 |
+12.41% |
---|
Pfizer Inc. shares have returned to important technical levels around 32.71 USD based on weekly price data. The timing seems attractive to be a buyer of this stock.
Summary● The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
Strengths● The share is getting closer to its long-term support in weekly data, at USD 32.71, which offers good timing for buyers.
● Share prices are approaching a strong support area in daily data, which offers good timing for investors.
● The group's activity appears highly profitable thanks to its outperforming net margins.
● Historically, the company has been releasing figures that are above expectations.
● This company will be of major interest to investors in search of a high dividend stock.
● Analysts covering this company mostly recommend stock overweighting or purchase.
● The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
● The tendency within the weekly time frame is positive above the technical support level at 32.71 USD
Weaknesses● The company's enterprise value to sales, at 4.22 times its current sales, is high.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.